A Sub-study of Investigational Agents in Programmed Cell Death-1/Ligand 1 Refractory Locally Advanced or Metastatic Urothelial Carcinoma

This sub-study is part of an umbrella platform study which is designed to evaluate investigational agents with or without pembrolizumab in participants with urothelial carcinoma who are in need of new treatment options. Sub-study 04A will enrol participants with locally advanced or mUC whose disease is resistant to treatment with programmed cell death-1/ligand 1 (PD-1/L1) … Continued